Optometrists in New Albany, MS Accepting Medicare
7 Optometrists found. Showing 1 - 7
 Dr. Terry Michael Joslin, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 103 E Bankhead St, New Albany, MS 38652 Phone: 662-534-5861 Fax: 662-534-2573 |
 Eye Center Of New Albany Optometrist Medicare: Medicare Enrolled Practice Location: 402 Doctors Dr, New Albany, MS 38652 Phone: 662-539-7771 Fax: 662-539-7256 |
Dr. Michael David Ware, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 402 Doctors Dr, New Albany, MS 38652 Phone: 662-539-7771 Fax: 662-539-7256 |
Dr. Terry M. Joslin Optometrist Medicare: Not Enrolled in Medicare Practice Location: 103 East Bankhead St., New Albany, MS 38652 Phone: 662-534-5861 |
Dr. Julie C. Brock Optometrist Medicare: Medicare Enrolled Practice Location: 109 State Highway 15 S, New Albany, MS 38652 Phone: 662-534-9288 Fax: 662-534-8341 |
 Dr. Robin D Bennett, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 486 W Bankhead St, New Albany, MS 38652 Phone: 662-534-0101 Fax: 662-534-8005 |
Dr. Michael D. Ware & Associates, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 402 Doctors Dr, New Albany, MS 38652 Phone: 662-539-7771 Fax: 662-539-7256 |
News Archive
IRS faces GOP criticism on health care tax credits
During a Capitol Hill hearing Thursday, House Republican lawmakers grilled the director of the Internal Revenue Service on his agency's ruling allowing qualified individuals to get tax credits to buy health insurance in federal health insurance exchanges.
Trial compares renal denervation to a sham procedure for treatment-resistant hypertension
Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further blood pressure reductions after RDN with a smaller increase in additional medications prescribed and less use of diuretics.
Shield Therapeutics files IND application with FDA to initiate ST10 Phase 3 study
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug application with the US Food and Drug Administration to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia in pre-dialysis patients with chronic kidney disease.
Texas ranks 4th in terms of aggregate Medicaid underfunding, according to Medicaid analysis
A new Eljay, LLC analysis of the nation's Medicaid program released by the American Health Care Association (AHCA) projects that Medicaid underfunds the actual cost of providing quality long term care in 2009 by $271.1 million in Texas, and that Texas seniors rank 4th in the nation in cumulative underfunding of this care.
› Verified 6 days ago
Chiropractors
Physical Therapists
Optometrists
Occupational Therapists
Podiatrists
Audiologists
Speech-Language Pathologists